By Yannis Jemiai, Natalia Muhlemann , Rajat Mukherjee , Pantelis Vlachos , Apurva Bhingare , Yuan Ji
Most people know that clinical drug discovery is usually conducted using either Frequentist or Bayesian methods. These two statistical paradigms have enjoyed a degree of competition historically, with some statisticians tauting the statistical rigor of Frequentist designs and others the intuitiveness and flexibility of Bayesian clinical trials. Recently, though, a number of hybrid methods have arisen, that leverage the benefits of both paradigms for singularly powerful clinical trials. There are benefits of these combined methods.